Research Article

Analysis of the Influencing Factors of Immunological Nonresponders in Wuhan, China

Table 2

The comparison of follow-up and baseline conditions of the study patients.

VariableBaselineFollow-up

Years since HIV diagnosis0.1 (0.1, 0.2)3.3 (2.0, 5.7)0.000
Years since HAART3.0 (1.8, 5.0)
Follow-up times15.0 (11.0, 22.0)
HAART options0.000
 3TC + TDF + EFV153 (69.5%)118 (53.6%)
 3TC + AZT + EFV30 (13.6%)27 (12.3%)
 NVP+3TC + AZT24 (10.9%)9 (4.1%)
 Others13 (5.9%)66 (30.0%)
Co-trimoxazole0.000
 Yes156 (70.9%)195 (88.6%)
 No64 (29.1%)23 (10.5%)
 Missing0 (0.0%)2 (0.9%)
Liver function impairment0.000
 Yes98 (44.1%)74 (33.3%)
 No124 (55.9%)125 (56.3%)
 Missing0 (0.0%)23 (10.4%)
Leukopenia0.000
 Yes91 (41.4%)46 (20.9%)
 No129 (58.6%)150 (68.2%)
 Missing0 (0.0%)24 (10.9%)
Anemia0.000
 Yes78 (35.5%)24 (10.9%)
 No144 (64.5%)174 (78.2%)
 Missing0 (0.0%)24 (10.9%)
Viral load (copies/ml)97830.0 (35476.0, 254172.0)0.0 (0.0, 20.0)0.000
CD4 counts (cells/μl)39.0 (20.3, 105.8)162.0 (128.3, 183.0)0.000
WBC count (×109/L)4.2 (3.3, 5.1)4.8 (4.0, 5.7)0.000
Plt count (×109/L)174.0 (135.8, 218.3)205.5 (170.3, 241.5)0.000
Hb count (g/L)128.0 (113.0, 140.0)144.0 (130.0, 153.0)0.000
Cr (μmol/L)71.8 (61.0, 82.5)70.0 (60.9, 82.0)0.393
TG (mmol/L)1.4 (0.9, 1.9)1.5 (1.0, 2.4)0.027
TC (mmol/L)3.8 (3.3, 4.3)4.4(3.8, 5.0)0.000
FPG (mmol/L)5.5(4.9, 6.4)5.5 (5.2, 6.3)0.159
AST (U/L)28.0 (21.0, 37.0)25.0 (20.0, 31.0)0.000
ALT (U/L)23.5 (14.0, 41.0)20.0 (14.0, 28.5)0.002
T.BIL (μmol/L)10.0 (7.5, 12.9)7.5 (5.6, 10.7)0.000

HAART, Highly active antiretroviral therapy; 3TC, Lamivudine; TDF, Tenofovir disoproxil; EFV, Efavirenz; AZT, Zidovudine; NVP, Nevirapine; WBC, White blood cell; Plt, Platelet; Hb, Hemoglobin; Cr, Creatinine; TG, Triglyceride; TC, Total cholesterol; FPG, Fasting plasma glucose; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; T.BIL, Total bilirubin. Data are presented as N (%) or Median (IQR). values were determined by χ2 test or Wilcoxon signed rank test.